BACKGROUND: Studies have been mixed on whether naturally acquired human papillomavirus (HPV) antibodies may protect against subsequent HPV infection. We performed a systematic review and meta-analysis to assess whether naturally acquired HPV antibodies protect against subsequent genital HPV infection (ie, natural immunity). METHODS: We searched the MEDLINE and EMBASE databases for studies examining natural HPV immunity against subsequent genital type-specific HPV infection in female and male subjects. We used random-effects models to derive pooled relative risk (RR) estimates for each HPV type. RESULTS: We identified 14 eligible studies that included >24,000 individuals from 18 countries that examined HPV natural immunity. We observed significant protection against subsequent infection in female subjects with HPV-16 (pooled RR, 0.65; 95% confidence interval, .50-.80) and HPV-18 (0.70; .43-.98) but not in male subjects (HPV-16: 1.22; .67-1.77 [P= .05 (test for heterogeneity)]; HPV-18: 1.50; .46-2.55; [P= .15]). We also observed type-specific protection against subsequent infection for a combined measure of HPV-6/11/31/33/35/45/52/58 in female subjects (pooled RR, 0.75; 95% confidence interval, .57-.92). Natural immunity was also evident in female subjects when analyses were restricted to studies that used neutralizing assays, used HPV persistence as an outcome, or reported adjusted analyses (each P< .05). CONCLUSIONS: HPV antibodies acquired through natural infection provide modest protection against subsequent cervical HPV infection in female subjects. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Studies have been mixed on whether naturally acquired human papillomavirus (HPV) antibodies may protect against subsequent HPV infection. We performed a systematic review and meta-analysis to assess whether naturally acquired HPV antibodies protect against subsequent genital HPV infection (ie, natural immunity). METHODS: We searched the MEDLINE and EMBASE databases for studies examining natural HPV immunity against subsequent genital type-specific HPV infection in female and male subjects. We used random-effects models to derive pooled relative risk (RR) estimates for each HPV type. RESULTS: We identified 14 eligible studies that included >24,000 individuals from 18 countries that examined HPV natural immunity. We observed significant protection against subsequent infection in female subjects with HPV-16 (pooled RR, 0.65; 95% confidence interval, .50-.80) and HPV-18 (0.70; .43-.98) but not in male subjects (HPV-16: 1.22; .67-1.77 [P= .05 (test for heterogeneity)]; HPV-18: 1.50; .46-2.55; [P= .15]). We also observed type-specific protection against subsequent infection for a combined measure of HPV-6/11/31/33/35/45/52/58 in female subjects (pooled RR, 0.75; 95% confidence interval, .57-.92). Natural immunity was also evident in female subjects when analyses were restricted to studies that used neutralizing assays, used HPV persistence as an outcome, or reported adjusted analyses (each P< .05). CONCLUSIONS:HPV antibodies acquired through natural infection provide modest protection against subsequent cervical HPV infection in female subjects. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
antibodies; cervix; human papillomavirus; natural immunity; serology
Authors: Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Sofie H Mooij; Olivia Landén; Fiona R M van der Klis; Marianne A B van der Sande; Hester E de Melker; Roel A Coutinho; Arne van Eeden; Martijn S van Rooijen; Chris J L M Meijer; Maarten F Schim van der Loeff Journal: J Infect Date: 2014-06-12 Impact factor: 6.072
Authors: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: Hilary A Robbins; Yan Li; Carolina Porras; Michael Pawlita; Arpita Ghosh; Ana Cecilia Rodriguez; Mark Schiffman; Sholom Wacholder; Troy J Kemp; Paula Gonzalez; John Schiller; Douglas Lowy; Mark Esser; Katie Matys; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Ligia A Pinto; Allan Hildesheim; Tim Waterboer; Mahboobeh Safaeian Journal: BMC Infect Dis Date: 2014-03-03 Impact factor: 3.090
Authors: Daniel C Beachler; Krystle A Lang Kuhs; Linda Struijk; John Schussler; Rolando Herrero; Carolina Porras; Allan Hildesheim; Bernal Cortes; Joshua Sampson; Wim Quint; Paula Gonzalez; Aimée R Kreimer Journal: Sex Transm Dis Date: 2017-07 Impact factor: 2.830
Authors: Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey Journal: Proc Natl Acad Sci U S A Date: 2017-12-05 Impact factor: 11.205
Authors: Melina J Windon; Tim Waterboer; Alexander T Hillel; Wade Chien; Simon Best; Charles Stewart; Lee Akst; Tanya Troy; Noemi Bender; Brett Miles; William R Ryan; Rajarsi Mandal; Karen Pitman; David W Eisele; Carole Fakhry; Gypsyamber D'Souza Journal: Hum Vaccin Immunother Date: 2019-03-19 Impact factor: 3.452
Authors: Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson Journal: Ann Intern Med Date: 2019-12-10 Impact factor: 25.391
Authors: Irene Man; Kari Auranen; Jacco Wallinga; Johannes A Bogaards Journal: Philos Trans R Soc Lond B Biol Sci Date: 2019-05-27 Impact factor: 6.237
Authors: Carmen Hidalgo-Tenorio; Jessica Ramírez-Taboada; Concepción Gil-Anguita; Javier Esquivias; Mohamed Omar-Mohamed-Balgahata; Antonio SamPedro; Miguel Lopez-Ruz; Juan Pasquau Journal: AIDS Res Ther Date: 2017-07-18 Impact factor: 2.250
Authors: Andrea Trevisan; João M G Candeias; Patrícia Thomann; Luisa L Villa; Eduardo L Franco; Helen Trottier Journal: J Med Microbiol Date: 2020-07 Impact factor: 2.472